These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30681474)

  • 1. FDA Approves New Antiviral for Influenza.
    Aschenbrenner DS
    Am J Nurs; 2019 Feb; 119(2):21. PubMed ID: 30681474
    [No Abstract]   [Full Text] [Related]  

  • 2. Baloxavir Marboxil (Xofluza) for Influenza.
    Erlich DR
    Am Fam Physician; 2019 Dec; 100(12):776-777. PubMed ID: 31845775
    [No Abstract]   [Full Text] [Related]  

  • 3. Sixty seconds on . . . baloxavir.
    Hawkes N
    BMJ; 2018 Oct; 363():k4531. PubMed ID: 30366947
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of baloxavir marboxil against influenza in children.
    Kakuya F; Haga S; Okubo H; Fujiyasu H; Kinebuchi T
    Pediatr Int; 2019 Jun; 61(6):616-618. PubMed ID: 31195429
    [No Abstract]   [Full Text] [Related]  

  • 5. Baloxavir: First Global Approval.
    Heo YA
    Drugs; 2018 Apr; 78(6):693-697. PubMed ID: 29623652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing the new anti-influenza drug, baloxavir marboxil.
    Fujita J
    Respir Investig; 2020 Jan; 58(1):1-3. PubMed ID: 31791907
    [No Abstract]   [Full Text] [Related]  

  • 7. New Drugs 2019, part 3.
    Hussar DA
    Nursing; 2019 Aug; 49(8):24-32. PubMed ID: 31268951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir heralds a new era in influenza virus biology.
    Kikuchi T; Watanabe A
    Respir Investig; 2019 Jan; 57(1):1-2. PubMed ID: 30396860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
    Locke SC; Splawn LM; Cho JC
    Drugs Today (Barc); 2019 Jun; 55(6):359-366. PubMed ID: 31250840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses].
    Reina J; Reina N
    Rev Esp Quimioter; 2019 Feb; 32(1):1-5. PubMed ID: 30676002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snatch-and-Grab Inhibitors to Fight the Flu.
    García-Sastre A
    Cell; 2019 May; 177(6):1367. PubMed ID: 31150614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
    Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
    Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Watanabe A; Ishida T; Hirotsu N; Kawaguchi K; Ishibashi T; Shishido T; Sato C; Portsmouth S; Tsuchiya K; Uehara T
    Antiviral Res; 2019 Mar; 163():75-81. PubMed ID: 30684563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.
    Yang T
    Ann Pharmacother; 2019 Jul; 53(7):754-759. PubMed ID: 30674196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
    Uehara T; Hayden FG; Kawaguchi K; Omoto S; Hurt AC; De Jong MD; Hirotsu N; Sugaya N; Lee N; Baba K; Shishido T; Tsuchiya K; Portsmouth S; Kida H
    J Infect Dis; 2020 Jan; 221(3):346-355. PubMed ID: 31309975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.
    Yoshii N; Tochino Y; Fujioka M; Sakazaki H; Maruyama N; Asai K; Kakeya H; Shintaku H; Kawaguchi T
    Intern Med; 2020; 59(12):1509-1513. PubMed ID: 32536677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling mitigation of influenza epidemics by baloxavir.
    Du Z; Nugent C; Galvani AP; Krug RM; Meyers LA
    Nat Commun; 2020 Jun; 11(1):2750. PubMed ID: 32487990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
    Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T
    Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
    Koshimichi H; Tsuda Y; Ishibashi T; Wajima T
    J Pharm Sci; 2019 May; 108(5):1896-1904. PubMed ID: 30557562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride.
    Hussar DA; Moyer MR
    J Am Pharm Assoc (2003); 2019; 59(1):141-144. PubMed ID: 30580925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.